Armistice Capital LLC increased its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 33.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 676,035 shares of the company’s stock after purchasing an additional 168,385 shares during the quarter. Armistice Capital LLC’s holdings in Mineralys Therapeutics were worth $24,533,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP acquired a new position in Mineralys Therapeutics during the 3rd quarter worth $2,873,000. SG Americas Securities LLC increased its holdings in shares of Mineralys Therapeutics by 130.7% during the fourth quarter. SG Americas Securities LLC now owns 230,795 shares of the company’s stock valued at $8,376,000 after purchasing an additional 130,758 shares during the period. Vanguard Group Inc. raised its stake in shares of Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock valued at $114,480,000 after purchasing an additional 692,550 shares in the last quarter. Citigroup Inc. lifted its holdings in Mineralys Therapeutics by 501.7% in the third quarter. Citigroup Inc. now owns 163,168 shares of the company’s stock worth $6,187,000 after purchasing an additional 136,050 shares during the period. Finally, Jennison Associates LLC lifted its holdings in Mineralys Therapeutics by 234.4% in the fourth quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock worth $45,677,000 after purchasing an additional 882,307 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Mineralys Therapeutics news, insider David Malcom Rodman sold 4,584 shares of Mineralys Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total value of $114,600.00. Following the transaction, the insider owned 57,095 shares in the company, valued at approximately $1,427,375. The trade was a 7.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares in the company, valued at $155,000. This represents a 32.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 165,707 shares of company stock worth $4,383,768. Corporate insiders own 18.94% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on Mineralys Therapeutics
Mineralys Therapeutics Trading Up 4.8%
Shares of Mineralys Therapeutics stock opened at $25.13 on Thursday. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65. The stock has a market cap of $2.07 billion, a PE ratio of -12.26 and a beta of 0.57. The company’s 50-day moving average price is $27.64 and its two-hundred day moving average price is $30.13.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.04. On average, equities analysts predict that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Stories
- Five stocks we like better than Mineralys Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report).
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
